NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.
暂无分享,去创建一个
A. Belger | J. Krystal | D. Charney | D. D’Souza | R. Berman | W. Abi-Saab | S. Madonick | I. Petrakis
[1] A. Belger,et al. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions , 2000, Biological Psychiatry.
[2] D. Cyril D’Souza,et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans , 1999, Psychopharmacology.
[3] K. Rasmussen,et al. The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal , 1999, Neuropharmacology.
[4] J. Krystal,et al. D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia. , 1998, Biological psychiatry.
[5] B. Moghaddam,et al. Glutamatergic Regulation of Basal and Stimulus‐Activated Dopamine Release in the Prefrontal Cortex , 1998, Journal of neurochemistry.
[6] K. Black,et al. Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[7] B. Moghaddam,et al. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.
[8] P. Blanchet,et al. Neostriatal mechanisms in Parkinson's disease , 1998, Neurology.
[9] M. Schachner,et al. Molecular mechanisms that underlie structural and functional changes atthe postsynaptic membrane duringsynaptic plasticity , 1998, Progress in Neurobiology.
[10] J. Krystal,et al. The NMDA antagonist model for schizophrenia: promise and pitfalls. , 1998, Pharmacopsychiatry.
[11] T. Chase,et al. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease , 1998, Neurology.
[12] N. Fountain,et al. Responses of deep entorhinal cortex are epileptiform in an electrogenic rat model of chronic temporal lobe epilepsy. , 1998, Journal of Neurophysiology.
[13] Takayoshi Kobayashi,et al. Cocaine: evidence for NMDA-, β-carboline- and dopaminergic-mediated seizures in mice , 1998, Brain Research.
[14] J. Coyle,et al. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. , 1998, The American journal of psychiatry.
[15] R. Gracely,et al. Analgesic and cognitive effects of intravenous ketamine-alfentanil combinations versus either drug alone after intradermal capsaicin in normal subjects. , 1998, Anesthesia and analgesia.
[16] M. MacDonald,et al. Huntingtin: a single bait hooks many species , 1998, Current Opinion in Neurobiology.
[17] D. Javitt,et al. The role of N-Methyl-D-Aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes , 1998, European Neuropsychopharmacology.
[18] W. Falk,et al. A preliminary study of D-cycloserine treatment in Alzheimer's disease. , 1998, The Journal of neuropsychiatry and clinical neurosciences.
[19] H. Monyer,et al. Differentiation of glycine antagonist sites of N-methyl-D-aspartate receptor subtypes. Preferential interaction of CGP 61594 with NR1/2B receptors. , 1998, The Journal of biological chemistry.
[20] P. Calabresi,et al. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: Implications for ischemia and Huntington's disease , 1998, Annals of neurology.
[21] P. Goldman-Rakic,et al. 204. Glutamate, dopamine, the frontal cortex, and schizophrenia , 1998, Biological Psychiatry.
[22] J. Krystal,et al. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. , 1998, Archives of general psychiatry.
[23] G. Lynch,et al. Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Correlations with Hippocampal Neuronal Activity , 1998, The Journal of Neuroscience.
[24] G. McCarthy,et al. Assessment of prefrontal activation by infrequent visual targets and non-target novel stimuli in schizophrenia: A functional MRI study , 1998, Schizophrenia Research.
[25] A. Rice,et al. NMDA receptor activation during status epilepticus is required for the development of epilepsy , 1998, Brain Research.
[26] D. Cyril D’Souza,et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans , 1998, Psychopharmacology.
[27] M. Wolf,et al. Amphetamine and D1 Dopamine Receptor Agonists Produce Biphasic Effects on Glutamate Efflux in Rat Ventral Tegmental Area: Modification by Repeated Amphetamine Administration , 1998, Journal of neurochemistry.
[28] J. Krystal,et al. 601 Glycine ketamine interactions in healthy humans , 1997, Schizophrenia Research.
[29] G. Konopka,et al. Mechanism and prevention of neurotoxicity caused by β-amyloid peptides: relation to Alzheimer's disease , 1997, Brain Research.
[30] U. Frey,et al. Hippocampal synaptic plasticity: role in spatial learning or the automatic recording of attended experience? , 1997, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[31] A. Malhotra,et al. Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine , 1997, Biological Psychiatry.
[32] J. Olney,et al. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. , 1997, Archives of neurology.
[33] P. Eide,et al. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery , 1997, Acta anaesthesiologica Scandinavica.
[34] Anil K Malhotra,et al. Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.
[35] J. Witkin,et al. Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice , 1997, Psychopharmacology.
[36] A. Stubhaug,et al. Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo , 1997, PAIN.
[37] N L Foster,et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease , 1997, Neurology.
[38] J. Yakel. Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription. , 1997, Trends in pharmacological sciences.
[39] Roberto Malinow,et al. Learning Mechanisms: The Case for CaM-KII , 1997, Science.
[40] C. Applegate,et al. Effects of Valproate, Phenytoin, and MK‐801 in a Novel Model of Epileptogenesis , 1997, Epilepsia.
[41] Bita Moghaddam,et al. Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.
[42] J. Davies. Remacemide hydrochloride: a novel antiepileptic agent. , 1997, General pharmacology.
[43] M. MacDonald,et al. Huntingtin Immunoreactivity in the Rat Neostriatum: Differential Accumulation in Projection and Interneurons , 1997, Experimental Neurology.
[44] J M Gorman,et al. Mechanisms underlying memory impairment in schizophrenia , 1997, Psychological Medicine.
[45] H S Chen,et al. Mechanism of memantine block of NMDA‐activated channels in rat retinal ganglion cells: uncompetitive antagonism. , 1997, The Journal of physiology.
[46] M. Weller,et al. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy , 1997, Biological Psychiatry.
[47] R. Bronen,et al. Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse—a preliminary report , 1997, Biological Psychiatry.
[48] M. Delong,et al. Functional and pathophysiological models of the basal ganglia , 1996, Current Opinion in Neurobiology.
[49] G. Aghajanian,et al. A Selective AMPA Antagonist, LY293558, Suppresses Morphine Withdrawal-Induced Activation of Locus Coeruleus Neurons and Behavioral Signs of Morphine Withdrawal , 1996, Neuropsychopharmacology.
[50] D. Javitt,et al. Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia , 1996, British Journal of Psychiatry.
[51] R. Spanagel,et al. Evidence for alcohol anti-craving properties of memantine. , 1996, European journal of pharmacology.
[52] S. Lipton,et al. NMDA receptors: from genes to channels. , 1996, Trends in pharmacological sciences.
[53] G. Freund,et al. Glutamate receptors in the frontal cortex of alcoholics. , 1996, Alcoholism, clinical and experimental research.
[54] C. Tamminga,et al. Absence of ketamine effects on memory and other cognitive functions in schizophrenia patients. , 1996, Journal of psychiatric research.
[55] Josep Rizo,et al. Synaptotagmins: C2-Domain Proteins That Regulate Membrane Traffic , 1996, Neuron.
[56] K. Mann,et al. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. , 1996, Archives of general psychiatry.
[57] S. Woods,et al. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. , 1996, European journal of pharmacology.
[58] S. Mercadante. Ketamine in cancer pain: an update. , 1996, Palliative medicine.
[59] N. Cairns,et al. Cortical NMDA receptor properties and membrane fluidity are altered in Alzheimer's disease. , 1996, Dementia.
[60] C. J. Schmidt,et al. Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. , 1996, The Journal of pharmacology and experimental therapeutics.
[61] D. Schroeder,et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease , 1996, Neurology.
[62] W. Fleischhacker,et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence , 1996, The Lancet.
[63] M. Mcdermott,et al. A controlled trial of remacemide hydrochloride in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.
[64] Herbert Weingartner,et al. NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.
[65] A. Alterman,et al. Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. , 1996, Drug and alcohol dependence.
[66] M. Hasselmo,et al. NMDA-dependent modulation of CA1 local circuit inhibition , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[67] G. Lynch,et al. Psychological effects of a drug that facilitates brain AMPA receptors , 1996, International clinical psychopharmacology.
[68] S. Hashtroudi,et al. d-Cycloserine enhances implicit memory in Alzheimer patients , 1996, Neurology.
[69] K. Fukunaga,et al. A role of Ca2+/calmodulin-dependent protein kinase II in the induction of long-term potentiation in hippocampal CA1 area , 1996, Neuroscience Research.
[70] Joseph T. Coyle,et al. The Glutamatergic Dysfunction Hypothesis for Schizophrenia , 1996, Harvard review of psychiatry.
[71] E. Nestler,et al. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[72] S. Potkin,et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[73] J. P. Apland,et al. Anticonvulsant effects of memantine and MK-801 in Guinea Pig hippocampal slices , 1995, Brain Research Bulletin.
[74] P. Stanton,et al. Long-term potentiation and N-methyl-d-aspartate receptors: Foundations of memory and neurologic disease? , 1995, Neuroscience & Biobehavioral Reviews.
[75] K. Rasmussen. The Role of the Locus Coeruleus and N-Methyl-D-Aspartic Acid (NMDA) and AMPA Receptors in Opiate Withdrawal , 1995, Neuropsychopharmacology.
[76] J. Olney,et al. Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.
[77] R. Huganir,et al. Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions , 1995, Neuroreport.
[78] R. Post,et al. Stress, Conditioning, and the Temporal Aspects of Affective Disorders , 1995, Annals of the New York Academy of Sciences.
[79] K. A. Trujillo. Effects of Noncompetitive N-Methyl-D-Aspartate Receptor Antagonists on Opiate Tolerance and Physical Dependence , 1995, Neuropsychopharmacology.
[80] R. Anwyl,et al. beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. , 1995, Neuroreport.
[81] J. Dostrovsky,et al. Effect of GPi pallidotomy on motor function in Parkinson's disease , 1995, The Lancet.
[82] H. Kubová,et al. Suppression of cortical epileptic afterdischarges by ketamine is not stable during ontogenesis in rats , 1995, Pharmacology Biochemistry and Behavior.
[83] W H Theodore,et al. Felbamate Monotherapy: Implications for Antiepileptic Drug Development , 1995, Epilepsia.
[84] S. Heinemann,et al. Cloning and characterization of chi-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[85] S. Akbarian,et al. Developmental and regional expression pattern of a novel NMDA receptor- like subunit (NMDAR-L) in the rodent brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[86] R. Herting,et al. Evaluation of Cycloserine in the Treatment of Alzheimer's Disease , 1995, Journal of geriatric psychiatry and neurology.
[87] J. Krystal,et al. Glycine Site Agonists of the NMDA Receptor: A Review , 1995 .
[88] I. Feinberg,et al. Intraperitoneal dizocilpine induces cortical spike-wave seizure discharges in rats , 1995, Neuroscience Letters.
[89] Carol A. Tamminga,et al. Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.
[90] S. Sagratella. NMDA antagonists: antiepileptic-neuroprotective drugs with diversified neuropharmacological profiles. , 1995, Pharmacological research.
[91] S. Southwick,et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. , 1995, The American journal of psychiatry.
[92] P. Kalivas,et al. D1 receptors modulate glutamate transmission in the ventral tegmental area , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[93] B. McEwen,et al. Effects of adrenal steroid manipulations and repeated restraint stress on dynorphin mRNA levels and excitatory amino acid receptor binding in hippocampus , 1995, Brain Research.
[94] N C Andreasen,et al. Symptoms of Schizophrenia: Methods, Meanings, and Mechanisms , 1995 .
[95] D R Medoff,et al. Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.
[96] J. Krystal,et al. Differentiating nmda dysregulation in schizophrenia and alcoholism using ketamine , 1995, Schizophrenia Research.
[97] G. Nowak,et al. Alterations in the N-methyl-d-asparatate (NMDA) receptor complex in the frontal cortex of suicide victims , 1995, Brain Research.
[98] J. Coyle,et al. The glutamatergic basis of human alcoholism. , 1995, The American journal of psychiatry.
[99] P. Kalivas,et al. Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. , 1995, Drug and alcohol dependence.
[100] H. Silver,et al. Effects of Biperiden and Amantadine on Memory in Medicated Chronic Schizophrenic Patients , 1995, British Journal of Psychiatry.
[101] G. Nowak,et al. Swim Stress Increases the Potency of Glycine at the N‐Methyl‐d‐Aspartate Receptor Complex , 1995, Journal of neurochemistry.
[102] R. Sofia,et al. Felbamate modulates the strychnine-insensitive glycine receptor , 1995, Epilepsy Research.
[103] F. Bloom,et al. Psychopharmacology: The Fourth Generation of Progress , 1995 .
[104] B. Moghaddam,et al. Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: Implications for tonic influence of glutamate on dopamine release , 1994, Synapse.
[105] B. Meldrum. The role of glutamate in epilepsy and other CNS disorders , 1994, Neurology.
[106] Y. Yoneda,et al. Preferential Induction by Stress of the N‐Methyl‐d‐Aspartate Recognition Domain in Discrete Structures of Rat Brain , 1994, Journal of neurochemistry.
[107] J. Joyce,et al. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[108] M. Papp,et al. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. , 1994, European journal of pharmacology.
[109] M. Millan,et al. Chemically-diverse ligands at the glycine B site coupled to N-methyl-d-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice , 1994, Neuroscience Letters.
[110] R. Sapolsky,et al. Glucocortcoids mediate the stress-induced extracellular accumulation of glutamate , 1994, Brain Research.
[111] M. Bear,et al. Synaptic plasticity: LTP and LTD , 1994, Current Opinion in Neurobiology.
[112] R. Kurlan,et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease , 1994, Annals of neurology.
[113] Richard L. Huganir,et al. Glutamate receptor phosphorylation and synaptic plasticity , 1994, Current Opinion in Neurobiology.
[114] P. Skolnick,et al. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. , 1994, The Journal of pharmacology and experimental therapeutics.
[115] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[116] G. Aghajanian,et al. Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: an in vivo microdialysis study , 1994, Brain Research.
[117] P. Skolnick,et al. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. , 1993, European journal of pharmacology.
[118] M. Papp,et al. New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. , 1993, Polish journal of pharmacology.
[119] G. Lynch,et al. Corticosterone Exacerbates Kainate‐Induced Alterations in Hippocampal Tau Immunoreactivity and Spectrin Proteolysis In Vivo , 1993, Journal of neurochemistry.
[120] J. Penney,et al. NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex , 1993, Neurobiology of Aging.
[121] T. Yamakura,et al. Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. , 1993, Neuroreport.
[122] P. Skolnick,et al. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. , 1993, The Journal of pharmacology and experimental therapeutics.
[123] J. Korf,et al. A single social stress-experience alters glutamate receptor-binding in rat hippocampal CA3 area , 1993, Neuroscience Letters.
[124] B. Moghaddam,et al. Stress Preferentially Increases Extraneuronal Levels of Excitatory Amino Acids in the Prefrontal Cortex: Comparison to Hippocampus and Basal Ganglia , 1993, Journal of neurochemistry.
[125] W. Carlezon,et al. D-cycloserine attenuates scopolamine-induced learning and memory deficits in rats. , 1993, Behavioral and neural biology.
[126] W. Schmidt,et al. D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task. , 1992, European journal of pharmacology.
[127] T. Kosten,et al. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. , 1992, Archives of general psychiatry.
[128] J. Marshall,et al. Elevated NMDA receptors in parkinsonian striatum. , 1992, Neuroreport.
[129] A. Alterman,et al. Amantadine may facilitate detoxification of cocaine addicts. , 1992, Drug and alcohol dependence.
[130] R. Ehrman,et al. Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride. , 1992, Addictive Behaviours.
[131] R. Sapolsky,et al. Corticosterone Enhances Kainic Acid‐Induced Calcium Elevation in Cultured Hippocampal Neurons , 1992, Journal of neurochemistry.
[132] C. Cotman,et al. N-methyl-d-aspartate receptor complex in the hippocampus of elderly, normal individuals and those with Alzheimer's disease , 1992, Neuroscience.
[133] T. Chase,et al. Glutamatergic therapy of Huntington's chorea. , 1992, Clinical neuropharmacology.
[134] O. Paulsen,et al. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. , 1992, The Journal of pharmacology and experimental therapeutics.
[135] Karl J. Friston,et al. Patterns of Cerebral Blood Flow in Schizophrenia , 1992, British Journal of Psychiatry.
[136] J. Penney,et al. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of huntington's disease , 1991, Annals of neurology.
[137] D. Javitt,et al. Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.
[138] P. Slater,et al. Binding to the glycine site of the NMDA receptor complex in brains of patients with Alzheimer's disease , 1991, Neuroscience Letters.
[139] Greenamyre Jt,et al. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. , 1991 .
[140] C. Haertzen,et al. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. , 1991, NIDA research monograph.
[141] K. Perry,et al. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. , 1991, European journal of pharmacology.
[142] A. Benabid,et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus , 1991, The Lancet.
[143] P. Francis,et al. Characterisation of the Glycine Modulatory Site of the N‐Methyl‐d‐Aspartate Receptor‐Ionophore Complex in Human Brain , 1991, Journal of neurochemistry.
[144] R. Faull,et al. Alzheimer's disease: Changes in hippocampal N-methyl-d-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors—an autoradiographic study , 1990, Neuroscience.
[145] F. F. Weight,et al. Inhibition of N-methyl-l-aspartate activated ion current by desmethylimipramine , 1990, Brain Research.
[146] C. Cotman,et al. β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage , 1990, Brain Research.
[147] Robert M. Sapolsky,et al. Glucocorticoid endangerment of hippocampal neurons is NMDA-receptor dependent , 1990, Brain Research.
[148] P. Skolnick,et al. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. , 1990, European journal of pharmacology.
[149] S. Gershon,et al. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[150] A. Carlsson,et al. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease , 1990, Trends in Neurosciences.
[151] Michael Davis,et al. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala , 1990, Nature.
[152] G. Aghajanian,et al. Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis , 1989, Brain Research.
[153] P. Skolnick,et al. Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors , 1989, Pharmacology, Biochemistry and Behavior.
[154] J. Kornhuber,et al. Regional distribution of [3H]MK-801 binding sites in the human brain , 1989, Brain Research.
[155] G White,et al. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. , 1989, Science.
[156] K. Grant,et al. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals , 1989, Pharmacology Biochemistry and Behavior.
[157] R. Johnson,et al. Excitatory amino acid neurotransmission. , 1988, Journal of medicinal chemistry.
[158] J. Penney,et al. Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[159] J. Gruzelier,et al. Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders. , 1988, Archives of general psychiatry.
[160] J. Olney,et al. Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists. , 1987, European journal of pharmacology.
[161] P. Ascher,et al. Glycine potentiates the NMDA response in cultured mouse brain neurons , 1987, Nature.
[162] R. Dingledine,et al. Involvement of N-methyl-d-aspartate Receptors in Involvement of N-methyl-d-aspartate Receptors in Epileptiform Bursting in the Rat Hippocampal Slice , 2008 .
[163] James V. Hinrichs,et al. Ketamine: behavioral effects of subanesthetic doses. , 1984, Journal of clinical psychopharmacology.
[164] A. Young,et al. A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.
[165] I. Whishaw,et al. Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients. , 1983, The Journal of nervous and mental disease.
[166] D. Lodge,et al. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate , 1983, British journal of pharmacology.
[167] S. Zukin,et al. Adverse reactions to ketamine Anaesthesia , 1981, Anaesthesia.
[168] R. Zukin,et al. Specific [3H]phencyclidine binding in rat central nervous system. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[169] S. J. Young,et al. Phencyclidine-induced psychosis. , 1978, The American journal of psychiatry.
[170] R. Post,et al. Cocaine, kindling, and psychosis. , 1976, The American journal of psychiatry.
[171] D. Greenblatt,et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. , 1976, Psychopharmacology bulletin.
[172] S. Vale,et al. Amantadine in depression. , 1971, Lancet.
[173] R. Knill-Jones,et al. Controlled trial of amantadine hydrochloride in Parkinson's disease. , 1970, Lancet.
[174] G. Rosenbaum,et al. Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.
[175] G A Gutman,et al. Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder? , 1998, Molecular Psychiatry.
[176] P. Herrling. Excitatory amino acids : clinical results with antagonists , 1997 .
[177] P. Skolnick,et al. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. , 1996, Pharmacopsychiatry.
[178] M. Rogawski,et al. Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. , 1996, The Journal of pharmacology and experimental therapeutics.
[179] L. Havelec,et al. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. , 1996, Neuropsychobiology.
[180] D. Lovinger,et al. Cellular and behavioral neurobiology of alcohol: receptor-mediated neuronal processes. , 1995, Clinical neuroscience.
[181] C. Finch,et al. Beta-amyloid precursor protein (APP) and APP-RNA are rapidly affected by glutamate in cultured neurons: selective increase of mRNAs encoding a Kunitz protease inhibitor domain. , 1995, Journal of molecular neuroscience : MN.
[182] R. Spanagel,et al. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. , 1995, Journal of neural transmission. Supplementum.
[183] T. Soderling. Calcium-dependent protein kinases in learning and memory. , 1995, Advances in second messenger and phosphoprotein research.
[184] C. Randolph,et al. D‐Cycloserine Treatment of Alzheimer Disease , 1994, Alzheimer disease and associated disorders.
[185] A. Korczyn,et al. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.
[186] R. Sapolsky. Chapter 2 Glucocorticoids, hippocampal damage and the glutamatergic synapse , 1990 .
[187] G. E. Alexander,et al. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. , 1990, Progress in brain research.
[188] R. Schottenfeld,et al. Amantadine and desipramine in the treatment of cocaine abusing methadone maintained patients. , 1990, NIDA research monograph.
[189] S. A. Turkanis,et al. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. , 1989, Life sciences.
[190] F. Tennant,et al. Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. , 1987, Archives of internal medicine.